2023-03-28 16:41:07 ET
- Mereo BioPharma Group press release ( NASDAQ: MREO ): FY GAAP EPS of -£0.06.
- As of December 31, 2022, the Company had cash and short-term deposits of £56.3 million
- Net loss attributable to equity holders for the year ended December 31, 2022 was £34.2 million, compared to a net profit of £12.7 million in 2021, primarily reflecting an operating loss of £43.6 million and a gain of £7.8 million
- Total ordinary shares outstanding at December 31, 2022 were approximately 625 million.
For further details see:
Mereo BioPharma Group GAAP EPS of -£0.06